本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
Lunit to establish new subsidiary, Lunit Europe Holdings, to expand sales network across Europe and strengthen global capabilities SEOUL, South Korea, Feb. 17, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a global provider of AI-powered cancer solutions, today announced its decision to establish a new subsidiary, Lunit Europe Holdings, following a board of directors meeting held on February 16. Lunit Inc. will hold 100% of the subsidiary's stake. While Lunit has previously managed its European business through its branch office, the establishment of Lunit Europe Holdings will lead the company's plans to expand its sales network in Europe and strengthen partnerships with global medical device companies. Lunit Europe Holdings will be based in Amsterdam, the Netherlands, and is due to begin full-scale local recruitment. In 2019 and 2020, Lunit obtained CE marks for its AI solutions for radiology—Lunit INSIGHT CXR and Lunit INSIGHT MMG, respectively—obtaining commercial approval in the European Union. Since then, Lunit has accelerated its presence in the European medical device market through various partnerships with global companies, as well as major clinical studies validating the effectiveness of Lunit's AI in helping radiologists to analyze chest x-ray and mammography images. With the formation of Lunit Europe Holdings, Lunit plans to expedite its business development across the European Union and the European Free Trade Association (EFTA). "Lunit's creation of a European subsidiary is a major initiative to boost our business agility and seize new business opportunities within the European market," said Brandon Suh, CEO of Lunit. "We expect our establishment of Lunit Europe Holdings to serve as a stepping-stone to increase our profitability by strengthening Lunit's global capabilities and brand awareness."
ROCKVILLE, Md., Feb. 16, 2023 /PRNewswire/ -- Tetracore, Inc. (Tetracore®) is pleased to announce its partnership with the United States Department of Agriculture's (USDA) Animal and Plant Health Inspection Service (APHIS) to provide a stock of PCR kits for both African Swine Fever (ASF) and Foot-and-Mouth Disease (FMD). These kits were purchased for use in the National Animal Vaccine and Veterinary Countermeasures Bank to ensure that the U.S. is prepared for a possible outbreak of a high-consequence Foreign Animal Disease (FAD). As the only USDA licensed PCR kits for these diseases, Tetracore's VetAlert™ ASF and FMD Diagnostic Test kits will be critical in minimizing the potentially devastating impacts of a FAD outbreak. The presence of ASF in the Dominican Republic represents a looming threat to the welfare of food production in the United States. Outbreaks of FMD and ASF can result in devastating economic consequences for the livestock industry. This threat necessitates readily available, accurate, and validated diagnostics. An immediate surge of incoming samples to animal health testing laboratories would quickly exhaust available countermeasures. To address the need for laboratory surge capacity in an outbreak scenario, the USDA has asked Tetracore to stock their USDA-licensed test kits for FMD and ASF. The VetAlert™ ASF and FMD Diagnostic Test kits have been updated using contemporary viral sequences, to ensure the test remains fit for purpose. These tests have been validated in studies with multiple reference laboratories. The VetAlert™ ASF and FMD Diagnostic Test kits were developed and commercialized by Tetracore scientists and are sold exclusively by Tetracore. About Tetracore, Inc. Tetracore is a biotechnology company specializing in the development and manufacture of diagnostic devices and assays for the detection of infectious diseases. Located in the Biotechnology Corridor in Rockville, Maryland. Tetracore was founded in 1998 by former United Nations Special Commission biological weapons inspectors and scientists of the Naval Medical Research Institute in Bethesda, Maryland. For more information, visit www.tetracore.com or contact us at jkelly@tetracore.com. ®Tetracore is a Registered Trademark and VetAlert is a Trademark of Tetracore, Inc.
Leading distributor of agricultural and construction machinery equipment selects Syncron Retail Inventory for optimized dealer inventory management that aligns aftermarket strategies with dealer networks for superior customer service. CHICAGO, Feb. 15, 2023 /PRNewswire/ -- Syncron today announced that Kubota Tractor Corporation, a United States distributor of agricultural and construction machinery equipment, has selected Syncron Retail Inventory to support its retail inventory management. As Kubota works to streamline supply chains and provide dealers with time-saving solutions to access its inventory and deliver parts quickly, this optimization allows Kubota customers to focus on what they do best: planting, feeding, building and caring for our world. Recognizing the benefits of an intelligent parts inventory optimization solution, Kubota understood there was room to enhance its retail inventory management operations. In selecting a new solution, Kubota was looking for an attentive, experienced team willing to partner with them. "We chose Syncron because of their experience in the agricultural equipment industry and their existing connectivity to our certified dealer business systems," said Dann Kemmann, director of parts, Kubota Tractor Corporation. "Syncron helps us keep our commitments to our dealers by streamlining our parts inventory to better deliver the right part to the right place and at the right time." With Syncron, Kubota gains an out-of-the-box solution to automate dealer stock replenishment, improve over-the-counter fill rates and increase visibility for all stakeholders. Rather than rely on multiple dealer business systems to forecast and plan parts inventory, Kubota and its dealers gain access to a comprehensive, easy-to-use platform with easy integration that improves productivity and eliminates waste. "With an intelligent parts inventory optimization solution that places parts where and when they're needed, dealers can focus on providing a superior customer experience," said Anneliese Schulz, chief revenue officer, Syncron. "Syncron Retail Inventory allows organizations like Kubota to streamline RIM processes and align with dealer networks, offering exceptional support and expertise during the implementation process and beyond." To learn more about Syncron Retail Inventory, visit https://www.syncron.com/solutions/retail-inventory-management. About SyncronSyncron accelerates leading manufacturers and distributors to capitalize on the world's new service economy. We optimize aftermarket business profitability and working capital, increase customer loyalty, and enable our customers to transition successfully to future service-driven business models. Syncron connects and synchronizes every aspect of aftermarket service with more than $3 billion in annual value creation across OEMs and distributors in automotive, construction, mining, agriculture and industrial equipment, medical devices, consumer durables, high-tech, aerospace, and other industries. Our Connected Service Experience (CSX) cloud platform offers leading aftermarket sales and service solutions to effectively plan, price, and service your customers. CSX Cloud offers our customers competitive differentiation through exceptional aftermarket service experiences while driving significant revenue and profit improvements into a manufacturer or distributor's business. The world's top brands trust Syncron, making it the largest privately-owned global leader in intelligent service lifecycle management SaaS solutions. For more information, visit syncron.com. About Kubota Tractor Corporation Kubota Tractor Corporation, Grapevine, Texas, is the U.S. marketer and distributor of Kubota-engineered and manufactured machinery and equipment, including a complete line of tractors of up to 200 Gross hp* performance-matched implements, compact construction equipment, consumer lawn and garden equipment, hay tools, commercial turf products and utility vehicles. For product literature or dealer locations, contact: Kubota Tractor Corporation, 1000 Kubota Drive, Grapevine, TX 76051, (888) 4-KUBOTA [(888) 458-2682], Ext. 900, or visit KubotaUSA.com.*factory estimated rating
SHENZHEN, China, Feb. 15, 2023 /PRNewswire/ -- Mindray (SZSE: 300760), one of the world's leading developers and providers of advanced medical devices and solutions, recently launched its first wireless handheld ultrasound system, the TE Air. Wireless handheld ultrasound system, TE Air, Innovation Untethered "Built from Mindray's leading technologies, the TE Air has made a historic breakthrough in the image quality level of handheld ultrasound, integrating professional-level image quality into a small and light wireless system. Its premium performance and wireless portability allow clinicians to diagnose anytime and anywhere with confidence," said Xujin He, General Manager of the Medical Imaging System Business Unit at Mindray. Designed specifically to meet the demand of global healthcare professionals for a higher-quality portable ultrasound device that is easy to use in multiple medical environments and delivers crisp point-of-care ultrasound (POCUS) imaging, the TE Air revolutionizes the way of using ultrasound by transforming a complicated ultrasound system into a small size device, while retaining its ability to meet higher clinical requirements. Powered by Mindray's eWave platform and 2nd generation Single Crystal technology, the TE Air delivers high-quality images with low power consumption for ultimate performance. Meanwhile, with the features of dedicated exam presets and comprehensive imaging modes, the TE Air allows clinicians to conduct ultrasound examinations more efficiently and offers more accurate decision-making assistance. The TE Air's wire-free design and compact size that easily fits in a pocket, high-level disinfection tolerance, and flexible charging for extreme mobility, empower clinicians to overcome the challenges brought by unexpected mobile clinical scenarios. The unique Air Capsule doubles as a protective case and a portable wireless charger that keeps the device running all day, taking only 35 minutes to fast charge the device. With an IP68-level waterproof and dustproof design, the device is fully immersible for high-level disinfection, suitable for hospital infection control. The TE Air App, available for Android and iOS, perfectly balances simplicity and efficiency by allowing one-handed operation in any location. The TE Air can connect with advanced devices such as the Mindray TEX20 Ultrasound System, enabling providers to overcome the limitations of cords and tight spaces while offering premium functionality. It can also seamlessly integrate with hospital information systems to help improve workflow. Furthermore, the de-identified data collected can be saved and shared to meet the needs of teaching, training, consultation, and case sharing.
Targeted metabolomics panels and assays provide absolute quantitation for advanced research into the relationship of metabolites to glucose metabolism MORRISVILLE, N.C., Feb. 14, 2023 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions that advance a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced the launch of its Glucose Portfolio, consisting of four specific products that each measure the metabolomic aspects of glucose tolerance and insulin resistance and offer a comprehensive characterization of what occurs at a cellular level to drive glucose metabolism, which has implications for diabetes, heart disease, and neuropathy. The newly launched Metabolon Glucose Portfolio is comprised of four panels and assays, including: Diabetes Research Markers Targeted Panel: This panel offers absolute quantitation of 22 metabolites in a single blood sample, allowing customers to quantify the levels of key analytes recognized as bioactive promoters and detractors for healthy glucose metabolism. It provides confident, reproducible quantification of key analytes related to dysregulated glucose homeostasis, including lactoyl-phenylalanine which has been linked to several metabolic diseases, including diabetes. Impaired Glucose Tolerance Targeted Panel: Impaired glucose tolerance is a prediabetic state of hyperglycemia that is associated with insulin resistance and an increased risk of cardiovascular disease. The condition occurs when blood glucose levels remain high for an extended period after oral ingestion of glucose but are not high enough to be diagnosed as type 2 diabetes. This panel can be used with a single fasted blood sample and measures eight analytes, including glucose. Insulin Resistance Targeted Panel: Insulin resistance is a critical pathophysiological state underlying several chronic conditions, including type 2 diabetes, cardiovascular disease (CVD), hypertension, and polycystic ovarian syndrome (PCOS). Insulin resistance is evident when glucose builds up in the bloodstream instead of being absorbed by the body's cells and is a result of a diminished response to the hormone insulin. This panel identifies insulin resistance with a single fasting blood sample and quantifies insulin levels and three additional key analytes linked to insulin resistance. Salivary Glucose Single Analyte Assay: Daily monitoring of glucose levels is an essential part of managing diabetes. However, blood glucose testing usually involves finger pricks, an invasive procedure that is troublesome to some patients. This single analyte assay offers a non-invasive method by testing salivary glucose levels and provides detection levels that are two orders of magnitude lower than those found in blood. "Metabolomics holds the key to unlocking a deeper understanding of health and disease. At Metabolon, we harness the power of this cutting-edge science to revolutionize healthcare and improve outcomes for patients, worldwide," said Rangaprasad (Ranga) Sarangarajan, Ph.D., Chief Scientific Officer at Metabolon. "With the launch of our new Glucose Portfolio, we extend our mission to find innovative solutions to tackle diabetes, as well as other diseases where glucose tolerance and insulin resistance correlate with disease pathology." To learn more about how Metabolon deciphers thousands of discrete chemical signals from genetic and non-genetic factors to discover biomarkers and reveal biological pathways, visit https://www.metabolon.com/. About Metabolon Metabolon, Inc. is the global leader in metabolomics, with a mission to deliver biochemical data and insights that expand and accelerate the impact of life sciences research. Over 20 years, 10,000+ projects, 2,800+ publications, and ISO 9001:2015 and CLIA certifications, Metabolon has developed industry-leading scientific, technology, and bioinformatics techniques. Metabolon's Global Discovery Panel is enabled by the world's largest proprietary metabolomics reference library. Metabolon's industry-leading data and translational science expertise help customers and partners address some of the most challenging and pressing questions in the life sciences, accelerating research and enhancing development success. The company offers scalable, customizable metabolomics and lipidomics solutions supporting customer needs from discovery through clinical trials and product life-cycle management. For more information, please visit www.metabolon.com and follow us on LinkedIn and Twitter. About MetabolomicsMetabolomics, the large-scale study of all small molecules in a biological system, is the only 'omics technology that provides a complete current-state functional readout of a biological system. Metabolomics helps researchers see beyond the genetic variation of individuals, capturing the combined impact of genetic as well as external factors such as the effect of drugs, diet, lifestyle, and the microbiome on human health. By measuring thousands of discrete chemical signals that form biological pathways in the body, metabolomics can reveal important biomarkers enabling a better understanding of a drug's mechanism of action, pharmacodynamics, and safety profile, as well as individual responses to therapy.
Company to Utilize its New Edison™ System with Advanced Imaging Features for Use in Kidney Tumors MINNEAPOLIS, Feb. 13, 2023 /PRNewswire/ -- HistoSonics, (www.histosonics.com), the developer of a non-invasive platform and novel sonic beam therapy called histotripsy, announced today the US Food and Drug Administration (FDA) has approved the company sponsored #HOPE4KIDNEY Trial which is designed to evaluate the safety and technical success of the Edison System in targeting and destroying targeted primary renal tumors, completely non-invasively and without the need for incisions or needles. FDA approval of the #HOPE4KIDNEY IDE Trial comes after the company recently submitted results to the agency from their #HOPE4LIVER Trials where the studies met both primary endpoints of safety and efficacy in destroying targeted liver tumors. Example of HistoSonics technology targeting kidney tissue to be destroyed in a non-invasive histotripsy procedure. "We are very pleased with the FDA's approval of our #HOPE4KIDNEY Trial and appreciative of the agency's prompt review process. This approval represents a substantial milestone for our company as we continue to expand histotripsy and its potential benefits into diseases that impact the lives of so many people," commented Mike Blue, President and CEO of HistoSonics. Blue added, "We are excited to expand on our experiences in successfully targeting and treating in the liver using our enhanced Edison platform that combines advanced imaging and targeting capabilities with real time treatment monitoring. The kidney is a logical next application as treating in the kidney has very similar procedural and anatomical considerations as the liver, and Edison was specifically designed to treat anywhere in the abdomen, as a starting point. In addition, the prevalence of kidney disease remains high with many patients kept in active surveillance or watchful waiting." In the United States there are an estimated 600,000 people living with tumors of the kidney and renal pelvis with rates of new cases increasing since the 1990's. Current therapies such as partial nephrectomy and thermal ablation are invasive and exhibit complications from bleeding and infection that non-invasive histotripsy may avoid. While surgical intervention is the "gold standard" in removing kidney tumors, a non-invasive approach with histotripsy provides the potential to destroy targeted tissue without damaging non-targeted kidney tissue. Additionally, histotripsy's purely mechanical mechanism of cellular destruction could preserve function of the kidney's urine collecting system and eliminate certain complications seen with existing invasive approaches. HistoSonics' image guided sonic beam therapy system uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control. The science of histotripsy uses focused sound energy to produce controlled acoustic cavitation that mechanically destroys and liquifies targeted liver tissue at sub-cellular levels. The company believes that the novel mechanism of action of their proprietary technology provides significant advantages to patients, including the ability of the treatment site to recover and resorb quickly. Uniquely, the HistoSonics' platform also provides physicians the ability to monitor the destruction of tissue under continuous real-time visualization and control, unlike any modality that exists today. The Edison System is not currently available for sale. It is pending FDA review for a destruction of liver tissue indication. The #HOPE4KIDNEY trial is expected to support a future expansion of the indication to include the destruction of kidney tissue. About HistoSonics HistoSonics is a privately held medical device company developing a non-invasive platform and proprietary sonic beam therapy utilizing the science of histotripsy, a novel mechanism of action that uses focused ultrasound to mechanically destroy and liquify unwanted tissue and tumors. The company is currently focused on the continued development of its EdisonTM Platform, global clinical studies, and new strategic projects including future clinical applications and platforms. HistoSonics has offices in Ann Arbor, Michigan and Minneapolis, MN. For more information please visit: www.histosonics.com
A12 藝術空間
Medical Equipment
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
